Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer

Background Circulating endothelial cells and microparticles have prognostic value in cancer, and might be predictors of response to chemotherapy and antiangiogenic treatments. We have investigated the prognostic value of circulating endothelial cells and microparticles in patients treated for advanced non-small cell lung cancer. Methodology/Principal Findings Peripheral blood samples were obtained from 60 patients before first line, platinum-based chemotherapy +/− bevacizumab, and after the third cycle of treatment. Blood samples from 60 healthy volunteers were also obtained as controls. Circulating endothelial cells were measured by an immunomagnetic technique and immunofluorescence microscopy. Phosphatidylserine-positive microparticles were evaluated by flow cytometry. Microparticle-mediated procoagulant activity was measured by the endogen thrombin generation assay. Results: pre- and posttreatment levels of markers were higher in patients than in controls (p<0.0001). Elevated levels of microparticles were associated with longer survival. Elevated pretreatment levels of circulating endothelial cells were associated with shorter survival. Conclusions/Significance Circulating levels of microparticles and circulating endothelial cells correlate with prognosis, and could be useful as prognostic markers in patients with advanced non-small cell lung cancer.

[1]  S. Matsusaka,et al.  Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer , 2011, Cancer Chemotherapy and Pharmacology.

[2]  C. Marosi,et al.  Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  György Nagy,et al.  Cellular and Molecular Life Sciences REVIEW Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles , 2022 .

[4]  J. Brahmer,et al.  Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer , 2011, Cancer investigation.

[5]  L. Papazian,et al.  High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome , 2011, Critical care.

[6]  M. Macey,et al.  Flow cytometric analysis of microparticle phenotype and their role in thrombin generation , 2011, Cytometry. Part B, Clinical cytometry.

[7]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[8]  C. Tinelli,et al.  Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Haubitz,et al.  Circulating endothelial cells: markers and mediators of vascular damage. , 2010, Current stem cell research & therapy.

[10]  R Lacroix,et al.  Standardization of platelet‐derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  Chun Yang,et al.  Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells , 2010, Cancer biology & therapy.

[12]  F. Bertolini,et al.  Circulating endothelial cells as biomarkers in clinical oncology. , 2010, Microvascular research.

[13]  A. Rossi,et al.  The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. , 2010, Current medicinal chemistry.

[14]  A. Goldhirsch,et al.  Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab , 2009, Clinical Cancer Research.

[15]  D. Neuberg,et al.  Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.

[16]  S. Oudard,et al.  Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. , 2009, European urology.

[17]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[18]  J. Rak,et al.  Microvesicles: Messengers and mediators of tumor progression , 2009, Cell cycle.

[19]  Y. Ohe,et al.  Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Jacopo Meldolesi,et al.  Shedding microvesicles: artefacts no more. , 2009, Trends in cell biology.

[21]  I. Bauerfeind,et al.  Platelet-derived microparticles and coagulation activation in breast cancer patients , 2008, Thrombosis and Haemostasis.

[22]  J. Colon,et al.  Tissue factor‐bearing microparticles derived from tumor cells: impact on coagulation activation , 2008, Journal of thrombosis and haemostasis : JTH.

[23]  L. Horstman,et al.  Microparticle‐mediated thrombin generation assay: increased activity in patients with recurrent thrombosis , 2008, Journal of thrombosis and haemostasis : JTH.

[24]  C. Rao,et al.  Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[25]  S. Eichinger,et al.  Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer , 2006, Thrombosis and Haemostasis.

[26]  R. Bertina,et al.  Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.

[27]  M. Haubitz,et al.  Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  G. Lip,et al.  Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. , 2006, Neoplasia.

[29]  C. Sáez,et al.  Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.

[30]  Nigel Mackman,et al.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.

[31]  J. Freyssinet,et al.  Cellular microparticles: a disseminated storage pool of bioactive vascular effectors , 2004, Current opinion in hematology.

[32]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[33]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[34]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[35]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[36]  A. Schroit,et al.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.

[37]  E. Voest,et al.  Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  H. K. Kim,et al.  Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. , 2003, European journal of cancer.